Alcon has introduced Tryptyr (acoltremon ophthalmic solution) 0.003% in the United States for managing dry eye disease (DED), following its approval by the US Food and Drug Administration in late May 2025. The product is designed for the relief of both the signs and symptoms associated with DED and is packaged in single-dose vials, with a recommended administration of 1 drop per eye twice daily. This new offering by Alcon is anticipated to be a significant innovation in the treatment landscape for dry eye disease, as it is the first neuromodulator eye drop that can rapidly boost natural tear production, with effects noticeable as early as day one.
Lisa Praeger, the vice president and general manager of U.S. ocular health pharmaceutical at Alcon, expressed excitement about Tryptyr, highlighting its unique mechanism of action and the company’s dedication to providing a broad range of dry eye products. Praeger emphasized Alcon’s ability to deliver innovation to eye care professionals and the vast number of patients seeking relief from dry eye disease. The approval of Tryptyr was based on robust data from two phase 3 clinical trials, COMET-2 and COMET-3, where the solution demonstrated a significant increase in natural tear production within just one day of use. Patients treated with acoltremon ophthalmic solution experienced a substantial rise in tear production compared to those using the vehicle.
The neuromodulator in Tryptyr operates by stimulating corneal sensory nerves to prompt a swift increase in natural tear production following application. This novel mechanism of action addresses the root cause of dry eye disease, offering patients a fast-acting solution to their symptoms. Healthcare professionals, such as Paul Karpecki, OD, have acknowledged the importance of such innovations in providing effective options for the millions of individuals suffering from dry eye disease. Alcon has launched an extensive campaign targeted at eye care providers to highlight the rapid onset of natural tear production achieved with Tryptyr, equipping them with essential tools and resources to support patients in need.
The launch of Tryptyr aligns with Alcon’s commitment to supporting eye care providers by offering access initiatives like a dedicated field access management team to assist with fulfillment and a First Fill Free trial program for eligible patients prescribed the solution. Additionally, ongoing co-pay support will be provided for eligible patients seeking refills. This comprehensive approach underscores Alcon’s dedication to improving the management of dry eye disease and ensuring that healthcare professionals have the necessary resources to integrate new treatments seamlessly into their practices. Preeya K. Gupta, MD, commended Alcon for expanding treatment options for dry eye disease and providing clinicians with the educational support required to incorporate innovative therapies like Tryptyr effectively.
Key Takeaways:
– Tryptyr is a newly launched prescription treatment by Alcon for dry eye disease, aiming to enhance natural tear production rapidly.
– The product’s approval was based on positive results from phase 3 clinical trials, demonstrating its effectiveness in increasing tear production early in treatment.
– Alcon’s comprehensive support for eye care providers includes access initiatives and patient assistance programs to ensure broad availability and affordability of Tryptyr.
– Healthcare professionals have praised Tryptyr’s novel mechanism of action and swift relief for patients struggling with dry eye disease.
Tags: biotech
Read more on ophthalmologytimes.com